On March 2, 2023 Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA) technology for electrophysiology and the treatment of atrial fibrillation, reported it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023 (Press release, Pulse Biosciences, MAR 2, 2023, View Source [SID1234628088]). Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at View Source